We simulate the human gut microbiome.

Through digital twin technology, we identify condition-specific metabolic targets and design research-backed, food-grade microbiome formulations to support outcomes across gastrointestinal, ocular, urological, cognitive, mental health and beyond.
Contact Us

Our Unique Formula

Human gut microbiota + Digital twin technology x Artificial intelligence = Next-Generation Nutraceuticals
Human gut microbiota
+
Digital twin technology
x
Artificial intelligence
=
Next-Generation Nutraceuticals
  • Human Gut Microbiota
The human gut microbiota is a dynamic biological ecosystem that transforms food into bioactive metabolites. We start by characterizing microbial composition and metabolic capacity, treating the microbiome as a living system that can be guided—not overridden.
  • Digital Twin Technology
We create digital twins of real human microbiomes to simulate how specific ingredients are metabolized. This allows us to identify condition-specific key metabolites and trace them back to feasible, food-grade nutritional precursors—before entering the clinic or production.
  • Artificial Intelligence
Artificial intelligence integrates large-scale microbiome data, metabolic networks, and literature-validated mechanisms. By modeling thousands of scenarios in silico, AI enables us to design targeted, research-backed nutraceutical formulations with predictable biological outcomes.

Next-Generation Nutraceuticals

Prediction

Microbiome data → Digital twin simulation → Metabolic flux prediction

Design

Retrosynthhesis of food-grade substrates → Minimal precusor set discovery → Personalized ingredient combinations
Enbiosis microbiome database dietary & phenotype date integration Metabolome database Genome-scale microbial models Individual microbiome fingerprinting

Refinement

Iterative optimisation → Simulation- validated refinement

Discovery

Target metabolites → Retrosyntheses search → Precursor discovery

Clinical Studies

Our science is validated through carefully designed clinical studies focused on meaningful biological and health outcomes.
Contact Now
Learn More

Areas of Focus

Focus Area

Timeline

Ophthalmology
Mid-2026
Dry Eye Disease. Age-related Macular Degeneration (AMD). Diabetic Retinopathy Glaucoma. Cataract
Mid-2026
Urology
Mid-2026
Chronic Prostatitis. Chronic Pelvic Pain Syndrome
Mid-2026
Gastrointestinal
Mid-2026
IBD
Mid-2026
Metabolic / Endocrine
Mid-2026
Diabetes Mellitus
Mid-2026
Dermatology
2027
Eczema. Psoriasis
2027
Neurological / Cognitive
2027
Alzheimer’s Disease. Parkinson’s Disease
2027

Publications

Our microbiome intelligence platform has been evaluated through clinical studies and peer-reviewed publications, confirming both biological relevance and translational impact.

Next-Generation Nutraceuticals

Enbiosis microbiome database

Dietary & phenotype data integration Metabolome database (>30,000 compounds) Genome-scale microbial models (GSMMs) Individual microbiome fingerprinting
Iterative optimization
→ Simulation-validated refinement

Retrosynthesis of food-grade substrates

Minimal precursor set discovery Personalized ingredient combinations Microbiome-driven nutraceutical design Evidence-based formulation output
Target metabolites
→ Retrosynthesis search
→ Precursor discovery

Digital twin microbiome simulations

Al-driven metabolic pathway analysis Identification of dysregulated pathways Target metabolite selection Microbial species prioritization
Iterative optimization
→ Simulation-validated refinement